Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Fosun Pharma Shanghai March 2026 Securities Movement Monthly Report: Total share capital remains stable, potential issuance space exists for H-share option plan
Zhongfang Net data
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. submitted a monthly report on securities changes for the period ended March 31, 2026 on April 2, 2026. The report shows that the company’s total statutory/registered share capital remained unchanged at RMB 2,670,429,325, consisting of two parts: A shares and H shares. Of these, the statutory A-share capital is RMB 2,118,488,825, corresponding to 2,118,488,825 shares with a par value of RMB 1 each; the statutory H-share capital is RMB 551,940,500, corresponding to 551,940,500 shares with a par value of RMB 1 each.
As of the end of March 2026, the company’s total issued shares outstanding (excluding treasury shares) are 2,670,429,325, consistent with the total statutory shares. Specifically, 2,118,488,825 A shares have been issued, and 551,940,500 H shares have been issued. During the month, neither the number of issued shares nor the number of treasury shares changed.
According to the company’s 2025 A-share option scheme, as of the end of March, the number of outstanding options yet to be exercised is 4,446,400. If all are exercised, up to 1,145,200 A shares may be issued. During the month, no new shares were issued as a result of exercising these options. Meanwhile, under the 2025 H-share restricted share unit scheme, as of the end of the reporting period, a total of 10,382,200 restricted share units had been granted but not yet vested, representing rights to acquire an equivalent number of H shares. During the month, this scheme also did not lead to the issuance of new shares or the transfer of treasury shares.
The company confirms that its public float in H shares satisfies the requirements of the Listing Rules, namely that it is not less than 5% of the total number of issued shares in the H-share category (excluding treasury shares). The report was submitted by Tricor Investor Services Limited, the company’s H-share share transfer and registration agent.
Abundant information and precise analysis—available on the Sina Finance App